Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Lupin gets USFDA...

    Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-12-18T17:36:30+05:30  |  Updated On 18 Dec 2018 5:36 PM IST
    Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction

    New Delhi: Drug maker Lupin recently said it has received tentative approval from the US health regulator for Tadalafil tablets, used to treat erectile dysfunction and enlarged prostate, in the American market.


    The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Eli Lilly and Company's Adcirca tablets.


    Read Also: Lupin receives tentative US FDA approval for Apixaban Tablets, 2.5 mg and 5 mg


    Tadalafil is used to treat the symptoms of two conditions found in men: benign prostatic hyperplasia (BPH) and erectile dysfunction(ED). Tadalafil is also used to treat pulmonary arterial hypertension (PAH).


    According to IQVIA MAT September data, Adcirca tablets, 20 mg, had annual sales of around USD 503.8 million in the US.


    Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


    Read Also: Lupin receives tentative USFDA nod for Dimethyl Fumarate Delayed-Release Capsules

    Adcirca tabletBSEerectile dysfunctionIQVIALupinprostateTadalafil tabletsUS Food and Drug AdministrationUSFDA
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok